Skin laceration adverse event reports that record this term

Kind of term: MedDRA preferred term
Plain meaning: a cut in the skin

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 10,614 adverse event reports that record the MedDRA preferred term Skin laceration. In plain words, the term means: a cut in the skin. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 886 reports in the 12 months to June 2026 and 822 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Plain meaning

A cut in the skin. The words are from the fixed dictionary of this site. They add nothing to a report.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 113 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Skin laceration name as a suspect product, in order of name
Drug	Class	Reports with this term
Abatacept	Selective T cell costimulation modulator	53
Abreva	Non-Standardized chemical allergen	34
Acetaminophen		35
Actemra	Interleukin-6 receptor antagonist	345
Advate		87
Alendronate sodium	Bisphosphonate	39
Ambien	gamma-Aminobutyric acid A receptor positive modulator	41
Ambrisentan	Endothelin receptor antagonist	27
Amlodipine	Calcium channel blocker	31
Ampyra	Potassium channel blocker	32
Apixaban	Factor Xa inhibitor	71
Arava	Antirheumatic agent	106
Arimidex	Aromatase inhibitor	29
Aspirin	Nonsteroidal anti-inflammatory drug	44
Atorvastatin		41
Atorvastatin calcium	HMG-CoA reductase inhibitor	51
Avonex	Interferon beta	117
Azathioprine	Purine antimetabolite	43
Azithromycin	Macrolide antimicrobial	29
Carbidopa levodopa	Aromatic amino acid	52
Certolizumab pegol	Tumor necrosis factor blocker	38
Cimzia	Tumor necrosis factor blocker	65
Clonazepam	Benzodiazepine	110
Cosentyx	Interleukin-17A antagonist	88
Covid-19 Vaccine		25
Cymbalta	Serotonin and norepinephrine reuptake inhibitor	46
Dexamethasone	Corticosteroid	44
Diazepam	Benzodiazepine	32
Diltiazem		54
Diltiazem hydrochloride	Calcium channel blocker	31
Duodopa		31
Duopa	Aromatic amino acid	62
Dupixent	Interleukin-4 receptor alpha antagonist	257
Eligard	Gonadotropin releasing hormone receptor agonist	36
Eliquis	Factor Xa inhibitor	209
Enbrel	Tumor necrosis factor blocker	441
Entresto	Angiotensin 2 receptor blocker	36
Flonase	Histamine-1 receptor antagonist	34
Flonase Allergy Relief		28
Forteo	Parathyroid hormone analog	71
Fosamax	Bisphosphonate	78
Furosemide	Loop diuretic	36
Gabapentin	Anti-epileptic agent	50
Gilenya	Sphingosine 1-phosphate receptor modulator	30
Gold	Standardized chemical allergen	69
Gold Sodium Thiomalate		32
Hemlibra		120
Humalog	Insulin analog	28
Human immunoglobulin g	Human immunoglobulin G	146
Human Immunoglobulin G Hyaluronidase Recombinant Human		31
Humira		767
Hydromorphone		28
Hydroxychloroquine	Antimalarial	78
Hydroxychloroquine sulfate	Antimalarial	62
Ibuprofen	Nonsteroidal anti-inflammatory drug	37
Imbruvica	Kinase inhibitor	219
Inflectra	Tumor necrosis factor blocker	98
Infliximab	Tumor necrosis factor blocker	84
Jakafi	Janus kinase inhibitor	52
Kisqali	Kinase inhibitor	29
Leflunomide	Antirheumatic agent	56
Lenalidomide	Thalidomide analog	28
Levetiracetam		32
Lipitor	HMG-CoA reductase inhibitor	26
Lorazepam	Benzodiazepine	35
Lyrica		41
Mepolizumab	Interleukin-5 antagonist	68
Metformin	Biguanide	43
Metformin hydrochloride	Biguanide	54
Methotrexate	Folate analog metabolic inhibitor	256
Methotrexate sodium	Folate analog metabolic inhibitor	37
Morphine sulfate	Opioid agonist	42
Nuplazid	Atypical antipsychotic	70
Ocrelizumab	CD20-directed cytolytic antibody	25
Ocrevus	CD20-directed cytolytic antibody	156
Omalizumab	Anti-IgE	110
Opsumit	Endothelin receptor antagonist	56
Orencia	Selective T cell costimulation modulator	132
Otezla	Phosphodiesterase 4 inhibitor	39
Oxycodone hydrochloride	Opioid agonist	30
OxyContin	Opioid agonist	34
Pantoprazole	Proton pump inhibitor	27
Plaquenil	Antimalarial	44
Plavix	P2Y12 platelet inhibitor	30
Pomalyst	Thalidomide analog	31
Prednisone	Corticosteroid	236
Rebif	Interferon beta	39
Remicade	Tumor necrosis factor blocker	168
Remodulin	Prostacycline vasodilator	42
Repatha	PCSK9 inhibitor	34
Revlimid	Thalidomide analog	136
Rinvoq	Janus kinase inhibitor	138
Rituxan	CD20-directed cytolytic antibody	59
Rituximab	CD20-directed cytolytic antibody	195
Rosuvastatin	HMG-CoA reductase inhibitor	66
Rosuvastatin calcium	HMG-CoA reductase inhibitor	68
Sandostatin LAR Depot		35
Seroquel	Atypical antipsychotic	37
Simponi	Tumor necrosis factor blocker	39
Skyrizi	Interleukin-23 antagonist	183
Stelara	Interleukin-12 antagonist	61
Sulfasalazine	Aminosalicylate	82
Tecfidera		58
Tiotropium bromide	Anticholinergic	49
Tymlos		26
Tysabri	Integrin receptor antagonist	94
Vedolizumab	Integrin receptor antagonist	66
Venclexta	BCL-2 inhibitor	45
Vioxx		103
Xarelto	Factor Xa inhibitor	67
Xeljanz	Janus kinase inhibitor	112
Xiaflex		61
Xolair	Anti-IgE	78

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 50 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Skin laceration name, in order of name
Class	Reports with this term
Aminosalicylate	87
Angiotensin 2 receptor blocker	85
Anti-epileptic agent	103
Anti-IgE	188
Anticholinergic	62
Antimalarial	184
Antirheumatic agent	162
Aromatic amino acid	124
Atypical antipsychotic	222
Benzodiazepine	209
beta-Adrenergic blocker	73
Biguanide	97
Bisphosphonate	131
Calcium channel blocker	65
CD20-directed cytolytic antibody	456
Corticosteroid	446
Endothelin receptor antagonist	105
Factor Xa inhibitor	359
Fluoroquinolone antibacterial	50
Folate analog metabolic inhibitor	293
GLP-1 receptor agonist	74
Histamine-1 receptor antagonist	93
HMG-CoA reductase inhibitor	252
Human immunoglobulin G	173
Insulin analog	55
Integrin receptor antagonist	163
Interferon beta	172
Interleukin-12 antagonist	63
Interleukin-17A antagonist	106
Interleukin-23 antagonist	200
Interleukin-4 receptor alpha antagonist	268
Interleukin-5 antagonist	89
Interleukin-6 receptor antagonist	369
Janus kinase inhibitor	320
Kinase inhibitor	455
Loop diuretic	64
Nonsteroidal anti-inflammatory drug	195
Opioid agonist	259
P2Y12 platelet inhibitor	80
Parathyroid hormone analog	71
Potassium channel blocker	59
Prostacycline vasodilator	118
Proton pump inhibitor	79
Purine antimetabolite	51
Selective T cell costimulation modulator	185
Serotonin and norepinephrine reuptake inhibitor	77
Serotonin reuptake inhibitor	88
Standardized chemical allergen	69
Thalidomide analog	195
Tumor necrosis factor blocker	959

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Skin laceration, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Skin laceration
Age	Reports	Share
Under 2	20	0.2%
2 to 11	125	1.2%
12 to 17	126	1.2%
18 to 44	1,121	10.6%
45 to 64	2,291	21.6%
65 to 74	1,585	14.9%
75 and over	1,542	14.5%
Age not given	3,804	35.8%

Sex of the patient in the reports that record Skin laceration
Sex	Reports	Share
Female	5,503	51.8%
Male	4,166	39.3%
Unknown or not given	945	8.9%

Age and sex are as the report gives them. 69.3% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Skin laceration: adverse event reports that record this term. https://reportedreactions.com/reaction/skin-laceration/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 1 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Skin laceration mean in an adverse event report?

In plain words: a cut in the skin. It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page